MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/crd.0000000000001068

Медицинская библиотека · Cardiology in review · 2025

Finerenone and Its Cardiorenal Protective Effects: A Meta-Analysis of 21,731 Patients From Randomized Trials.

Rai Bibeka, Dar Salman Farooq, Alowami Moaz, Sajjad Roshail Bin, Agarwal Trishtha, Khan Muhammad Haris, Mubarak Ali Salman Riaz, Kamran Ghuncha, Thomas Renju Philip, Mudiyanselage Nipun Sanka Bandara Adikari, AlQudah Bashar, Khan Yumna Aziz, Behary Paray Nitish, Shahzad Maryam, Ahmed Mushood, Ahmed Raheel

СтатьяПеревод в очереди

Аннотация

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a promising therapy for patients with diabetes, chronic kidney disease, heart failure (HF), or diabetes. We aimed to summarize the current evidence on its cardiovascular (CV) and renal benefits. A systematic search of PubMed, Cochrane CENTRAL, Embase, and ClinicalTrials.gov was conducted up to July 21, 2024. Randomized controlled trials assessing finerenone's effects on CV and renal outcomes were pooled using a random-effects model, with results expressed as risk ratios (RRs) or mean differences (MDs) with corresponding 95% confidence intervals. Nine randomized controlled trials with 21,731 participants were included. Finerenone significantly reduced all-cause mortality (RR, 0.92; P = 0.03), major adverse CV events (RR, 0.85; P < 0.00001), and HF hospitalizations (RR, 0.82; P < 0.00001). It lowered the risk of sustained ≥57% estimated glomerular filtration rate decline (RR, 0.70; P = 0.01), slowed overall estimated glomerular filtration rate deterioration (MD, -1.65; P = 0.02), and reduced urine albumin-to-creatinine ratio (MD, -0.28; P < 0.00001). CV death showed a nonsignificant reduction (RR, 0.90; P = 0.05), while myocardial infarction risk (P = 0.37), adverse events (P = 0.40), and discontinuations (P = 0.45) were similar between groups. However, hyperkalemia risk was higher with finerenone (RR, 2.05; P < 0.00001). Finerenone provides significant cardiorenal benefits, reducing CV events, HF hospitalizations, and kidney disease progression in patients with chronic kidney disease, HF, and diabetes, with a favorable safety profile aside from increased hyperkalemia risk. These findings support its role as an effective add-on to standard cardiorenal therapies.

Для цитирования: Rai Bibeka, Dar Salman Farooq, Alowami Moaz, Sajjad Roshail Bin, Agarwal Trishtha, Khan Muhammad Haris, Mubarak Ali Salman Riaz, Kamran Ghuncha, Thomas Renju Philip, Mudiyanselage Nipun Sanka Bandara Adikari, AlQudah Bashar, Khan Yumna Aziz, Behary Paray Nitish, Shahzad Maryam, Ahmed Mushood, Ahmed Raheel. Finerenone and Its Cardiorenal Protective Effects: A Meta-Analysis of 21,731 Patients From Randomized Trials.. Cardiology in review. 2025. DOI: 10.1097/crd.0000000000001068.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.